Holocene Advisors
UTHR icon

Holocene Advisors’s United Therapeutics UTHR Stock Holding History

Holocene Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$845K Hold
1,559
– – ﹤0.01% 698
2026
Q1 		$924K Buy
1,559
+831
+114% +$414K ﹤0.01% 681
2025
Q4 		$355K Sell
728
-48,867
-99% -$22.8M ﹤0.01% 695
2025
Q3 		$20.8M Buy
49,595
+47,206
+1,976% +$15.9M 0.05% 259
2025
Q2 		$686K Buy
2,389
+804
+51% +$240K ﹤0.01% 678
2025
Q1 		$489K Buy
+1,585
New +$543K ﹤0.01% 679
2018
Q2 		– Sell
-2,287
Closed -$257K – 743
2018
Q1 		$257K Sell
2,287
-5,221
-70% -$663K 0.01% 427
2017
Q4 		$1.11M Buy
+7,508
New +$954K 0.03% 101

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Holocene Advisors's UTHR Position: Q2 2026 in Review

Holocene Advisors held its United Therapeutics (UTHR) position steady in Q2 2026 at 1,559 shares worth $845K. The position accounts for ﹤0.01% of the portfolio, ranked #698.

Holocene Advisors first reported a position in UTHR in Q4 2017 and has held it in 8 quarters since. The position peaked at $20.8M in Q3 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Holocene Advisors held 1,559 shares of United Therapeutics worth $845K as of Q2 2026.
  • Holocene Advisors left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up ﹤0.01% of Holocene Advisors's portfolio in Q2 2026, its #698 holding.
  • Holocene Advisors first reported a position in United Therapeutics in Q4 2017 and has held it in 8 quarters since.
  • Holocene Advisors's United Therapeutics position peaked at $20.8M in Q3 2025.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.